Login to Your Account

Riding high on new interim data suggesting plasma-derived alpha-1 antitrypsin (AAT) might help patients with graft-vs.-host disease (GvHD) recover when steroids fail, Omni Bio Pharmaceutical Inc. is angling to produce an irresistible proof-of-concept package showing its preclinical recombinant AAT (rAAT) could do the same and more.
LONDON – Autolus Ltd. has launched with a £30 million (US$45.6 million) series A funding to develop chimeric antigen receptor (CAR) T-cell cancer therapies, which it claims will both overcome the serious side effects seen to date and move beyond B-cell targeting to address solid tumors.

Carsgen, a Chinese developer of cancer therapies, announced its completion of an undisclosed series A financing led by China-based health care private equity fund BVCF Management Ltd. The proceeds will initiate the clinical trials of Carsgen's lead therapeutic.

More Newco News Headlines

Cast Your Vote

Has biotech’s bubble burst?: